Baroreflex Activation Therapy for the Treatment of HFrEF – When CRT Is Not an Option
Published: 05 July 2021
-
Views:
737 -
Likes:
7
-
Views:
737 -
Likes:
7
-
2m 58sPart 1 Welcome and Introduction Jörn Schmitt , Faiez Zannad, Michael Knaut, Ainhoa Robles Mezcua
Overview
In this webinar, cardiologists, heart failure specialists and electrophysiologists will go through this simple implantable device that electrically stimulates the carotid baroreflex to improve symptoms of HFrEF. The panel will discuss patient indication, our latest clinical data, and incorporation into clinical practice.
This webinar is supported by CVRx.
Key Learning Objectives
- Review the role of the baroreflex as a primary regulator of cardiovascular function and have a better understanding of the mode of action.
- Identify the patient indication for carotid baroreceptor stimulation in heart failure with reduced ejection fraction.
- Review the long term data and experience with baroreflex activation therapy in heart failure with reduced ejection fraction.
- Get to know the device, and the implantation procedure of BAROSTIM.
- Exchange with experienced physicians that prescribe and use BAROSTIM in their hospitals.
Target Audience
- Heart Failure Specialist
- Cardiologist
- Interventional Cardiologist
- Rhythmologist
More from this programme
Part 1
Welcome and Introduction
1 session | |
Welcome and Introduction | Watch now |
Part 2
Introduction: BAT Mode of Action & Patient Indication for HF
Part 3
Clinical Results (Presentation of clinical data on Heart Failure as HOPE4HF & BeAT-HF study)
Part 4
Device Presentation & Implant Procedure
Part 5
Case Study: advanced HF, ventricular arrhythmias and BAROSTIM
Part 6
Summary of Baroreflex Activation Therapy for HFrEF
Faculty Biographies
Jörn Schmitt
Electrophysiologist
Dr Schmitt is an Electrophysiologist with 10+ years of experience, working at the Clinical University of Giessen/Marburg, in Germany.